Ralf T.
- Country
- Germany
- Department
- Kinder- und Jugendmedizin
Research Overview
- A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis.
- Efficacy and Safety of Subcutaneous Ixekizumab Versus Adalimumab in Pediatric Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis
- Evaluation of Long-Term Safety and Efficacy of Baricitinib in Pediatric Patients with Juvenile Idiopathic Arthritis: A Phase 3 Multicenter Study
Data & Insights
Has run more than one trial at 31 of 81 partner sites.
Specializations
Pediatric Rheumatology
This investigator specializes in treating juvenile idiopathic arthritis (JIA) and its various subtypes, with particular expertise in managing complex inflammatory conditions in young patients.
- Juvenile Psoriatic Arthritis
- Enthesitis-related Arthritis
- Systemic JIA
The investigator's work extends to the evaluation of novel therapeutic approaches for pediatric rheumatic conditions.
Inflammatory Eye Disorders
The investigator has developed expertise in treating juvenile idiopathic arthritis-associated uveitis and related inflammatory eye conditions in pediatric populations.
- JIA-associated Uveitis
- Chronic Anterior Antinuclear Antibody-Positive Uveitis
Their research encompasses innovative therapeutic strategies for inflammatory eye disorders in children.
Autoimmune Conditions
The investigator focuses on treating complex autoimmune disorders in pediatric patients, particularly those affecting the musculoskeletal system.
- Juvenile-onset Ankylosing Spondylitis
- Inflammatory Arthritis
Their expertise includes evaluating biological therapies for pediatric autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.